Revelation Biosciences Q1 net loss $2.7M; cash $14.6M sufficient through 2024

REVELATION BIOSCIENCES, INC.

2024-Q1 EPS reported -$2.46

Net loss of $2.7M ($2.46 per share) for Q1 2024, compared to net earnings of $6.2M in Q1 2023, driven by change in warrant liability.
Cash and cash equivalents $14.6M as of March 31, 2024, up from $12.0M at December 31, 2023.
Net cash used in operating activities was $2.8M, up from $1.6M YoY, due to clinical study expenses for GEM-AKI and GEM-SSI.
Company believes current cash is sufficient to fund operations through 2024 based on current projections.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

REVELATION BIOSCIENCES, INC. reported the three months ended March 31, 2024 results: net income $2.7 million, EPS $2.46 basic and diluted net loss per share.

Period: the three months ended March 31, 2024
Net income: $2.7 million
EPS: $2.46 basic and diluted net loss per share
Result: reported results

Exact text from the filing

Revelation’s net loss for the three months ended March 31, 2024 was $2.7 million, or $2.46 basic and diluted net loss per share

View on SEC.gov

1048 earnings releases filed in the last 30 days. Browse all earnings releases →

REVELATION BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0000950170-24-057927

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.